Oral Iron Supplementation for Patients With Chronic Kidney Disease

Universidade Federal Fluminense

Status and phase: Active, not recruiting; Phase 2

Conditions: Anemia of Chronic Kidney Disease; Dysbiosis; Iron-Deficiency Anemia; Chronic Renal Disease

Treatments: Drug: Ferrous sulfate daily; Drug: Ferrous sulfate higher concentration; Drug: Ferrous sulfate 3 days week

Study type: Interventional

Funder types: Other

Identifiers

NCT05544513

DeniseMafra14

Details and patient eligibility

About

The hypothesis of this research is that oral iron prescribed in a single dose in alternate day could mitigate the side effects with regard to intestinal microbiota, inflammation, oxidative stress and improve the hematological profile when compared to daily oral iron prescription

Full description

chronic kidney disease triggers several changes in the body, anemia is one of the first disorders that appear in chronic kidney disease patients. The anemia in this patient is multifactorial, the main cause being relative erythropoietin deficiency, although iron deficiency is also common. In this context, the need for oral iron supplementation is a way of both treating iron deficiency and optimizing the use of agents that stimulate erythropoiesis. However, this replacement can cause iron overload, increasing the production of reactive oxygen species and, consequently, oxidative stress, and also alter the intestinal microbiota leading to poor iron absorption, worsening the prognosis of chronic kidney disease. The current routine for iron supplementation for these patients is to offer oral iron daily, which can be more harmful than when given on alternate days. However, there are few studies comparing the two prescriptions.

In this context, since no study to date has been carried out to show the aforementioned effects in the participant with chronic kidney disease, this randomized clinical trial aims to assess the effects of daily or alternate-day oral iron supplementation on gut microbiota composition in participants with chronic kidney disease (glomerular filtration rate (GFR) below 30 mL/min) for 3 months. The project will also compare the effects of both prescriptions on serum hepcidin levels, markers of oxidative stress and inflammation, and on routine hematological and biochemical parameters.

Enrollment: 6 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Aged 18 to 75 years Clinical diagnosis of Chronic Kidney Disease Conservative treatment group: chronic kidney disease stages 3 and 5

Exclusion criteria

• Patients pregnant
• Smokers
• Using antibiotics in the last 3 months
• Autoimmune diseases
• Clinical diagnosis of infectious diseases
• Clinical diagnosis of Cancer
• Clinical diagnosis of AIDS

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

6 participants in 3 patient groups

Group I

Experimental group

Description:

participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays

Treatment:

Drug: Ferrous sulfate 3 days week

Group II

Active Comparator group

Description:

participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)

Treatment:

Drug: Ferrous sulfate daily

Group III

Active Comparator group

Description:

participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays

Treatment:

Drug: Ferrous sulfate higher concentration